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Abstract
Objective Patient’s language, tradition, conventions, and
customs may all determine integration into a society and are
also part of the doctor–patient relationship that influences
diagnostic and therapeutic outcome. Language barrier and
sociocultural disparity of Eastern and Southern European
patients may hamper recovery from pain and depression
compared to Middle European patients in Switzerland.
Methods In a prospective naturalistic observational trial
we investigated the influence of regional origin on treat-
ment outcome in 420 pain sufferers with depressive
symptoms from all over Switzerland who were treated with
venlafaxine by 122 physicians in primary care. Physicians
rated severity of depressive symptoms using the clinical
global impression severity scale and pain intensity by
means of visual analogue scales. We hypothesized that in
Eastern and Southern European patients the magnitude of
pain reduction under treatment with venlafaxine is less
compared to Middle European patients.
Results Three months after study entry, Middle European
patients were found to profit more from treatment with
venlafaxine in terms of severity of depression and pain
intensity than patients from Eastern Europe and Southern
Europe.
Conclusion Regional origin may contribute to the mag-
nitude of pain reduction in patients with depressive
symptoms under treatment with venlafaxine. Our results
provide a rational for care provider educational programs
aimed at improving capacities in treating patients from
different regional origin with psychosomatic complaints
such as depression and comorbid pain.
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Introduction
A considerable number of immigrants from all over the
world have settled in Switzerland since the 1960s; many of
them recently immigrated from Balkan states and Turkey.
Migration is associated with an increased risk of chronic
pain [24]. Culture, ethnicity, and psychosocial environment
may all have an important effect on pain perception and
response [10, 28]. The risk of endorsing depressed mood in
patients with chronic pain is two to threefold increased
[4, 12]. Reported symptom clusters of depression differ in
various cultures [28]. Pain has an important impact on
response of depression to treatment in primary care [24],
and negatively influences pain perception in the long-term
[2, 30].
Treatment of chronic pain in patients with depressive
symptoms is inherently difficult to provide [2, 3], cost
intensive [14], and provided by various medical specialists
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amongst them primary care physicians (general practitioners
and internists, and psychiatrists) [3]. Excessive pain behav-
iour may lead to unnecessary diagnostic testing and invasive
procedures, and consequently iatrogenic complications
and prolonged disability. In addition to rehabilitative and
psychotherapeutic means, antidepressants may alleviate
pain in depressed patients [19]. Venlafaxine is one of the
most prescribed newer antidepressants and improves vari-
ous types of pain [1, 2, 11, 16, 22, 25, 27, 31]. Specifically, we
recently showed that venlafaxine decreased pain in a popu-
lation of depressed primary care patients, some of whom
participated also in the present study [7]. Empirically, many
physicians in Switzerland prescribe venlafaxine to their
patients with chronic pain, particularly if the patients
also show symptoms of depression. We recently found that
venlafaxine decreased pain in depressed primary care
patients who were in part also investigated in the present
study.
Patient’s language, tradition, conventions, and customs
may all determine the doctor–patient relationship, thereby
impacting diagnostic and therapeutic outcome. Doctors
behave comparably less affectively when interacting with
ethnic minority patients [26]. In turn, ethnic minority
patients are less verbally expressive and they seem also
to be less assertive and affective during the medical
encounter relative to the average population [26]. Ethnic
group identity is a predictor of locus of control which
may considerably influence pain perception [6]. By rea-
son of their language and sociocultural background,
Eastern and Southern European patients may be less
integrated into Swiss society than are immigrants from
Middle Europe. In addition to sociocultural factors, the
degree of integration into society affects the outcome of
pain disorder in patients with a history of migration [24].
Many immigrants from Eastern Europe fled from the
Balkan conflicts since 1991. Greater disease severity may
relate to the experience of organized violence during war-
and war-like conflicts [13]. Negative affectivity in gen-
eral has been proved to augment the burden of disease
[21].
In this observational study, we therefore assumed that
the magnitude of pain reduction in patients with depressive
symptoms under treatment with venlafaxine differently
relates to cultural regions of origin of patients. Naturalistic
studies focussing on the treatment of patients with chronic
pain and comorbid depressive symptomatology, investi-
gating the impact of regional origin on treatment outcome
in a primary care setting, are lacking. We hypothesized that
in consequence of disparate sociocultural background,
encountered challenges with integration into society, and
language barrier in the doctor–patient relationship, Eastern
European and Southern European patients would report
greater pain intensity and less improvement of pain under
treatment than those from Middle Europe. We statistically
controlled for several covariates possibly affecting pain
reduction, mainly the severity and duration of the disease,
the venlafaxine dose prescribed at endpoint, and the
duration of venlafaxine treatment.
Methods
Study design
The present study is part of a larger project which evalu-
ated the therapeutic efficacy of venlafaxine in patients
suffering pain and comorbid depressive symptoms [7]. For
this purpose sales representatives invited 170 physicians
from all regions in Switzerland among the medical speci-
alities of psychiatry, general practice, and internal
medicine. In Switzerland, venlafaxine is currently widely
prescribed for this patient group. Therefore, study partici-
pation of physicians and their patients was not subject to
incentives. Patients were included if they were newly
prescribed venlafaxine (mostly within 2 weeks before visit
1). No other in- and exclusion criteria were applied. The
proportion of contacted physicians working in the Italian,
French, and Swiss German speaking parts of Switzerland
was 1:3:6. Totally 122 physicians participated in the study
(accrual rate 72%). Each practitioner could include a
maximum of five patients and typically contributed four to
five patients to the study. Patients’ regional origin was
asked and, after completion of data sampling, divided into
three groups according to the respective Swiss publics
opinion of national similarities across countries: (a)
‘‘Middle Europe’’ (Switzerland, Germany, Austria); (b)
‘‘Eastern Europe’’ (incl. Greece, Turkey, and other); and
(c) ‘‘Southern Europe’’ (France, Italy, Spain, Portugal).
This observational study was conducted in accordance with
the Declaration of Helsinki and its amendments, consid-
ering the need for ethical approval and patient informed
consent.
As detailed below, physicians determined diagnosis of
depression by a regular clinical interview, estimated pain
intensity using a visual analogue scale (VAS), and rated
severity of depressive symptoms by the clinical global
impression scale (CGI). Age, gender, duration of depres-
sion, and all clinically approved diagnoses for comorbid
somatic and mental disorders (i.e. the first digit according
to ICD-10) were listed. The use of opioid and non-opioid
analgesics and the number of therapies in addition to those
targeting depression and pain were also recorded. Data
were obtained at study entry. Venlafaxine dosages and
CGI and VAS scores were also obtained at two follow-up
visits intended to take place at 1 and 3 months after study
entry.
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Study participants
Of totally 601 patients, participating in the parent study, we
report here on 420 patients who had conclusive information
available for CGI severity score and pain intensity scores at
study entry (also termed initial visit or visit 1), at the first
follow-up visit (also termed visit 2), and at the second
follow-up visit (also termed endpoint visit or visit 3),
and for the dosage of venlafaxine prescribed at visit 3
(according to available formulas of the substance and
commonly prescribed dosages coded as 1 = 0 mg, 2 = 1–
75 mg, 3 = 76–150 mg, or 4 = 151–450 mg), and time
between visit 1 and visit 3 in days. If data from visit 3 were
missing, the last observation from visit 2 was carried for-
ward to the endpoint (i.e. data of visit 2 were used as
endpoint measures for visit 3). Information was also
required to be complete for regional origin (coded as
1 = Middle Europe, 2 = Eastern Europe incl. Turkey, or
3 = Southern Europe), speciality of the treating physician
(coded as 1 = psychiatrist (PSY), 2 = general practitioner
(GP), or 3 = internist (IM)), gender, age, the number of
ICD-10 diagnosis other than related to pain or depression
(coded as 0, 1, or C2 diagnoses), duration of depressive
symptomatology, and time between visits allowing for full
analysis of covariance (ANCOVA). The use of prescribed
non-opioids, low potent opioids (i.e. tramadol, tilidine,
dihydrocodeine), and high-potent opioids (i.e. morphine,
buprenorphine, fentanyl, hydromorphone, oxycodone) (all
coded as 0 = no or 1 = yes), other therapies for pain or
depression (coded as 0 = no or 1 = yes), duration of
depressive symptoms in months, and duration of pain in
months were all assessed by physician report.
Psychometric assessment
Diagnosis of depression
Within the scope of the common diagnostic procedure in
Swiss primary care referring to conversant diagnostic cri-
teria for depression, physicians established the diagnosis of
depression based on history taking, the clinical interview,
and clinical impression of the patient. By reason of their
limited time resources within this naturalistic observational
study, they did not apply a structured diagnostic interview
tool to establish a diagnosis of depression.
CGI
CGI is a three-item scale used to assess treatment response
and can also be used for measuring the severity of a
depressive state [5]. Severity of Illness (item 1) is rated on
a seven-point scale (1 = normal to 7 = extremely ill);
global improvement (item 2) is rated on a seven-point scale
(1 = very much improved to 7 = very much worse); and
the efficacy index (item 3) is rated on a four-point scale
(from ‘none’ to ‘outweighs therapeutic effect’) [15].
VAS
Pain intensity was estimated in terms of the five main
body regions (i.e. back, extremities, head, abdomen, and
chest) by a VAS ranging from 0 (no pain) to 10 (extreme
pain). Since many patients suffering depressive symp-
tomatology and pain report pain in more than one region
of the body a total pain severity score was computed
by adding up the VAS scores of the five individual pain
regions.
Statistical analysis
We used SPSS 13.0 for Windows to analyse the data. A nor-
mal distribution could not be achieved for measures of
depression duration, pain duration, and time from visit 1 to
visit 3 by any transformation procedure. For these measures
we formed a categorical variable with each category including
a similar number of subjects to be used as a covariate in
repeated measures analyses of covariance (RM ANCOVA).
The categories were for the duration of depression: (1)
0–1 month (n = 108), (2) 2–7 months (n = 105), (3)
8–32 months (n = 101), and (4) 33–377 months (n = 106);
for the duration of pain: (1) 0–4 months (n = 112), (2)
5–18 months (n = 99), (3) 19–53 months (n = 105), and (4)
54–424 months (n = 104); and for the time from visit 1 to
visit 3: (1) 7–87 days (n = 107), (2) 88–94 days (n = 106),
(3) 95–106 days (n = 102), and (4) 107–413 days (n = 105).
All tests were two-tailed and the level of significance
was set at P \ 0.05. Pearson chi-square test, Kruskal–
Wallis test, and one-way ANOVA were used to examine
differences between regional origin in terms of categori-
cal and normally or non-normally distributed continuous
variables where appropriate. Changes in the CGI severity
and pain scores over time were examined using RM
ANCOVA with time (visit 1, visit 2, visit 3) as the within-
subjects factor and with regional origin (Middle Europe,
Eastern Europe, Southern Europe) as the between-
subjects factor controlling for CGI severity score at visit
1, the respective pain scores at visit 1, venlafaxine dosage
at endpoint, and the time elapsed between visit 1 and
visit 3. Demographic and medical covariates were gender,
age, physician speciality, use of non-opioid analgesics,
use of low and high-potent opioids combined, other
therapies for pain and depression, number of ICD-10
diagnosis other than related to pain and depression,
duration of depressive symptomatology, and duration of
pain. Fisher’s least significant difference was used for
post hoc testing.
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Results
Patient characteristics
The subsample of 420 patients investigated here did not
significantly differ from the total sample of 601 patients at
visit 1 in terms of origin, age, severity and duration of
depression, duration of pain, the number of ICD-10 diag-
noses other than depression and pain, the use of prescribed
analgesics (non-opioids, low- and high-potent opioids), and
other therapies for pain or depression. The subsample com-
prised a lower proportion of women; there were no gender
differences between sample and subsample with regard to
age and the medical characteristics reported above.
Patients were from Middle Europe in 58%, from Eastern
Europe incl. Turkey in 26%, and from Southern Europe in
16%. Table 1 shows the differences in demographic and
medical characteristics of the 420 patients studied by
regional origin.
Change in severity of depression
Figure 1 shows the interaction between time and regional
origin for the change in the CGI severity score between
visits 1 and 3 (F2,406 = 14.7, P \ 0.001). The magnitude
of the decrease in the CGI score over time was greater in
patients from Middle Europe than in those from the Eastern
Europe (P \ 0.001) and in those from Southern Europe
(P = 0.001), whereas no significant difference was
observed between Eastern European and Southern Euro-
pean patients.
Change in pain severity
There was an interaction between time and regional ori-
gin for a reduction in total pain severity from visit 1 to
visit 3 (F2,405 = 5.3, P = 0.005; Fig. 2a). The magnitude
of the decrease in total pain intensity over time was greater
in patients from Middle Europe than in those from the
Eastern Europe (P \ 0.001) and from Southern Europe
(P = 0.006); pain reduction was not significantly different
between Eastern European and Southern European
patients.
Separate analyses for the individual pain regions
revealed interactions between time and regional origin for a
decrease in severity of back pain (F2,405 = 9.5, P \ 0.001;
Fig. 2b), extremities pain (F2,405 = 7.4, P = 0.001;
Fig. 2c), and pain localised to the head (F2,405 = 5.6,
Table 1 Characteristics of the 420 patients by categories of regional origins
Middle Europe (n = 243) Eastern Europe (n = 108) Southern Europe (n = 69) P value
Women/men 63/37 57/43 61/39 0.567
Age (years) 54.5 ± 16.1 43.7 ± 8.8 50.2 ± 10.7 \0.001
Physician speciality (PSY, GP, IM) 18/59/23 42/39/19 20/60/20 \0.001
Duration of depression (months) 7 (1–41) 7 (2–23) 9 (1–40) 0.827
Duration of pain (months) 15 (3–52) 22 (6–47) 34 (7–66) 0.004
Non-opioid analgesics (years/n) 86/14 86/14 85/15 0.993
Low potent opioids (years/n) 23/77 30/70 26/74 0.417
High-potent opioids (years/n) 5/95 1/99 6/94 0.153
Other therapiesa 49/51 25/75 45/55 \0.001
ICD-10 diagnosis (0, 1 C2)b 37/33/30 59/31/10 43/35/22 \0.001
CGI severity score at visit 1 (1–7) 4.5 ± 0.9 4.9 ± 0.8 4.7 ± 0.9 0.001
Total pain at visit 1 (0–50) 13.9 ± 7.5 18.0 ± 7.8 19.2 ± 8.8 \0.001
Back pain at visit 1 (0–10) 4.8 ± 2.4 6.5 ± 2.9 6.5 ± 2.6 \0.001
Extremities pain at visit 1 (0–10) 3.5 ± 3.4 4.5 ± 3.4 5.0 ± 3.4 0.001
Head pain at visit 1 (0–10) 3.1 ± 3.1 4.8 ± 3.1 4.3 ± 3.3 \0.001
Abdomen pain at visit 1 (0–10) 1.4 ± 2.5 0.8 ± 1.9 1.7 ± 2.7 \0.001
Thoracic pain at visit 1 (0–10) 1.0 ± 2.1 1.3 ± 2.2 1.8 ± 2.3 \0.001
Venlafaxine dose at visit 3 (mg) 137.4 ± 64.0 160.7 ± 76.0 145.8 ± 71.3 0.020
Time between visit 1 and 3 (days) 94 (87–109) 93 (84–104) 96 (88–111) 0.637
Values are given as mean ± SD, median (with inter-quartile range), or percentage. Analyses used either Pearson chi-square test, Kruskal–Wallis
test, or one-way analysis of variance
CGI clinical global impression, GP general practice, ICD international classification of diseases, IM internal medicine, PSY psychiatry
a Other than for pain or depression
b Other than related to pain or depression
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P = 0.004; Fig. 2d). Reduction in pain severity localised
to the back (P \ 0.001) and to the head (P B 0.002) was
greater in patients from Middle Europe than in those from
the Eastern Europe and from Southern Europe. In addition,
reduction in extremities pain was greater in patients from
Middle Europe than in those from the Eastern Europe
(P \ 0.001). There were no significant changes over time
in pain severity localised to the abdomen and thorax.
Patients from the Eastern Europe and from Southern
Europe did not significantly differ in changes of any pain
score.
Discussion
Supporting our hypothesis, Eastern European and Southern
European patients showed less therapeutic benefit in terms
of a decrease in the CGI severity score and overall
pain intensity compared to their Middle European coun-
terparts when controlling for a series of covariates possibly
affecting severity of depression, pain perception and
chronic manifestation. The magnitude of the decrements in
the CGI and VAS scores was clinically meaningful. One
point decrease from 4 to 3 on the CGI indicates change
from moderate to mild impairment, whereas the decrement
of two points in the VAS score is considered to be a rel-
evant pain reduction [31].
We offer three possible explanations for these finding,
even if these not ultimately derive from our results. First,
successful treatment of chronic pain is based on a multi-
level approach that confers various rehabilitative and
psychotherapeutic means in addition to the expected ben-
efits of drug treatment. Therefore, the doctor–patient
relationship may play an important role in delivering
advice, and in establishing diagnostic and therapeutic
procedures. By reason of language difficulties and
disparate sociocultural background, the doctor–patient
relationship might have been hampered mostly in Eastern
European patients. Second, psychosocial conditions in the
host country affect the outcome of pain disorders. Eastern
European patients in Switzerland have comparably less
accomplished integration because of language difficulties,
sociocultural disparity, and most recent migration. It could
previously be shown that psychosocial background [6, 13,
26] and the degree of integration into society [24] may
influence pain behaviour. Third, in this observational study,
we did not differ between distinct kinds of chronic pain.
But, psychiatrists treated the highest percentage of Eastern
European patients (42%) compared to general practitioners
(39%) and internists (19%). According to the Swiss care
providing system, psychiatrists are referred patients with
chronic pain after these have undergone treatment by
general practitioners and internists. Therefore, even if this
reasoning remains speculative, we may suggest that East-
ern European patients suffer more from somatoform pain
than the two other patient groups because somatoform
pain in general is difficult to treat, especially by internists
who received comparably few training in the clinical
management of psychiatric disorders. Supporting this third
explanation, compared to Middle European and Southern
European patients, Eastern European patients were
younger, showed higher intensity of depressive symptoms,
endorsed a comparably lower number of diagnoses in
addition to depression and pain, and received a lower
number of other therapies for depression and chronic pain.
In contrast, relatively more frequent care to Middle Euro-
pean and Southern European patients was provided by a
general practitioner. The latter two patient groups received
also more frequently therapies for conditions above and
beyond depression and pain.
In terms of pain intensities of different body regions at
endpoint, Middle European patients suffered less from
back and head pain than Eastern and Southern European
patients, and Middle European patients had lower intensity
of extremities pain than Southern European patients. To
interpret these data, we suppose a relation to a different
way of pain behaviour and expression, and doctor–patient
interaction as previously shown [10, 13, 24, 26, 28]. There
were no significant changes over the study period of
3 months in pain severity localised to the abdomen and
Fig. 1 The graph shows the significantly different mean ± SEM
decrease in the clinical global impression (CGI) severity score over
time between regional origins after adjustment for covariates (cf.
text). The CGI severity score decreased significantly less in patients
from Eastern Europe (EE) and from Southern Europe (SE) compared
to those from Middle Europe (ME)
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thorax between the three patients groups. This could be
explained by the comparably low levels of abdominal and
thoracic pain in our sample at study entry and may not
reflect cultural differences in pain experience or psycho-
social interactions with the host country. In fact, only about
one-third of all patients reported thoracic and abdominal
pain with mostly minimal intensity.
Even if Eastern and Southern European patients, in
accordance with greater severity of pain and depressive
symptoms at study entry, received on average slightly
higher mean doses of venlafaxine at endpoint, they
improved less in terms of depression and pain compared to
Middle European patients. There was a strong relationship
between depression and pain improvement. However,
even when taking into account depression and pain at
study entry, Eastern and Southern European patients still
improved less during treatment with venlafaxine. We did
not monitor compliance based on plasma levels of venla-
faxine or compliance questionnaires. Yet, during the study,
3 of 108 patients from Eastern Europe and 3 of 69 patients
from Southern Europe dropped out, whereas only 217 of
243 Middle European patients could be followed up to visit
3. Therefore, worse compliance in Eastern and Southern
European compared to Middle European patients as a
possible confounder seems unlikely. In sum, neither com-
pliance during the study nor severity of depression or pain
at study entry seem to explain our finding of a less
favourable outcome in Eastern and Southern European
compared to Middle European patients. Instead, based on
our consideration above and as delineated in the intro-
duction, we interpret our findings rather to be due to certain
other factors. These might relate to somatoform pain that is
particularly difficult to treat and may be more prevalent in
Eastern and Southern European patients, as well as to
unfavourable ethnic and cultural factors which impact the
doctor–patient communication [6, 24, 26] at the beginning
and during treatment such as to worsen outcome [8, 9, 13].
In addition underdose of antidepressants in general was
previously reported in primary care settings [18, 29] and
might also play a particular role in patients from Eastern
and Southern Europe.
Our data should be interpreted within the particular
limitations of the study design. A psychiatric diagnosis of
depression was not formally established by a structured
Fig. 2 The graphs show the
significantly different
mean ± SEM decreases in pain
intensity scores over time
between regional origins after
adjustment for covariates (cf.
text). Intensity of total pain (a),
back pain (b), and head pain (d)
decreased all significantly less
in patients from Eastern Europe
(EE) and from Southern Europe
(SE) compared to patients from
Middle Europe (ME).
Extremities pain decreased
significantly less in Eastern
European patients than in
Middle European patients (c)
22 Soc Psychiat Epidemiol (2010) 45:17–24
123
interview. Also, the number of ICD-10 diagnoses is a
rather crude measure to reliably account for the ‘‘true’’
comorbidity. Furthermore, we did not consider duration of
stay and family relations in the host country, socioeco-
nomic differences, and treatment for depression and pain
prior to inclusion in the study and during the observational
phase besides venlafaxine. Overall, Eastern European
patients were more severely ill at study entry than Middle
European patients but experienced less benefit from treat-
ment. This is particularly intriguing since Eastern European
patients received, on average, the highest dose of venla-
faxine in accordance with the state of the art suggesting dose
augmentation with increasing severity of the disease [20, 23],
even if dosage may still be too low for causing a satisfying
effect. This finding has to be interpreted bearing in mind
that our study was observational and lacked a control group
treated with an antidepressant other than venlafaxine.
The pragmatic study design represents the unequal
caring situation for patients with chronic pain and comor-
bid depressive symptomatology in Switzerland. Our results
are based on a sample size recruited from all Swiss regions
and by the physician specialities primarily involved in
management of these patient groups. Our data could par-
ticularly encourage primary care providers to deal with
these, for the healthcare system, challenging and costly
patients, who may draw at least equally strong health
benefit from both somatic primary care as from psychiatry.
Our results provide a rational for education programs tar-
geting at care providers who are involved in the treatment
of patients from different regional origins with psychoso-
matic complaints [17].
Conclusion
Bearing in mind the study limitations, we may conclude
that regional origin may contribute to the magnitude of
pain reduction in patients with depressive symptoms under
treatment with venlafaxine. Even though Eastern European
patients were more severely ill than Middle European
patients at study entry, and Eastern European and Southern
European patients had greater pain than Middle European
patients, Eeastern European and Southern European
patients experienced less benefit from treatment compared
to their Middle European counterparts.
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